Back to Research

Organization profile

Haya Therapeutics

Haya Therapeutics is a clinical-stage biotechnology company that develops precision RNA-guided therapies targeting the "dark genome" to treat chronic and age-related diseases. The company utilizes a proprietary platform to identify and drug long non-coding RNAs (lncRNAs) that act as master regulators of pathological cell states in tissues such as the heart and lungs.

Epalinges, SwitzerlandFounded 2019

Overview

1. Executive Summary (Confidence: High)

Haya Therapeutics is a pioneering precision medicine company focused on "Programming Lasting Health" through the exploration of the regulatory genome, also known as "genome dark matter". Headquartered in Lausanne, Switzerland, with laboratories in San Diego, Haya utilizes a multimodal functional genomics platform to decode the 98% of the human genome that does not code for proteins. Having successfully raised $65 million in Series A funding, the company is advancing its lead candidate, HTX-001, into clinical trials for heart failure, specifically targeting cardiac fibrosis. By drugging long non-coding RNAs (lncRNAs) that causally drive disease, Haya aims to reprogram "sick" cell states back to healthy ones, offering a new paradigm for treating common, chronic, and age-associated conditions.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.